Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 539.6 g/mol |
|---|---|
| Molecular Formula | C31H33N5O4 |
| XLogP3 | 3.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 539.25325455 g/mol |
| Monoisotopic Mass | 539.25325455 g/mol |
| Topological Polar Surface Area | 94.2 A^2 |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 947 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Ofev |
| Drug Label | OFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin... |
| Active Ingredient | Nintedanib |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg; 100mg |
| Market Status | Prescription |
| Company | Boehringer Ingelheim |
| 2 of 2 | |
|---|---|
| Drug Name | Ofev |
| Drug Label | OFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin... |
| Active Ingredient | Nintedanib |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg; 100mg |
| Market Status | Prescription |
| Company | Boehringer Ingelheim |
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
HSK44459 is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): HSK44459,Nintedanib Esylate,Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HSK44459,Nintedanib Esylate,Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HSK44459 is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of idiopathic pulmonary fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The collaboration aims to advance Nintedanib for idiopathic pulmonary fibrosis by targeting platelet-derived growth factor receptor, vascular endothelial growth factor receptor, and fibroblast growth factor receptor.
Lead Product(s): Nintedanib Esylate,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Apotex Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nintedanib Esylate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Apotex Inc
Deal Size : Undisclosed
Deal Type : Collaboration
DifGen and Apotex Announce FDA Approval of Generic Nintedanib Soft Gel Capsules, 100mg and 150mg
Details : The collaboration aims to advance Nintedanib for idiopathic pulmonary fibrosis by targeting platelet-derived growth factor receptor, vascular endothelial growth factor receptor, and fibroblast growth factor receptor.
Product Name : Ofev-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
OFEV-Generic (Nintedanib Esylate) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Nintedanib Esylate,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: OFEV-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nintedanib Esylate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nintedanib Capsules Approved and Launched
Details : OFEV-Generic (Nintedanib Esylate) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of idiopathic pulmonary fibrosis.
Product Name : OFEV-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ENV-101 (Taladegib) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Taladegib,Nintedanib Esylate,Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: ENV-101
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taladegib,Nintedanib Esylate,Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ENV-101 (Taladegib) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of idiopathic pulmonary fibrosis.
Product Name : ENV-101
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
MNKD-201 (Nintedanib) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Nintedanib Esylate,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MNKD-201
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 15, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nintedanib Esylate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MNKD-201 (Nintedanib) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of idiopathic pulmonary fibrosis.
Product Name : MNKD-201
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 15, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BMS-986353 (Zolacaptagene Autoleucel) is a cell & gene therapy drug, which is currently being evaluated in Phase III clinical studies for the treatment of scleroderma, systemic.
Lead Product(s): Zolacaptagene Autoleucel,Fludarabine Phosphate,Cyclophosphamide,Tocilizumab,Rituximab,Nintedanib Esylate
Therapeutic Area: Immunology Brand Name: BMS-986353
Study Phase: Phase IIIProduct Type: Cell & Gene Therapy
Sponsor: Celgene Corporation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zolacaptagene Autoleucel,Fludarabine Phosphate,Cyclophosphamide,Tocilizumab,Rituximab,Nintedanib Esylate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986353 (Zolacaptagene Autoleucel) is a cell & gene therapy drug, which is currently being evaluated in Phase III clinical studies for the treatment of scleroderma, systemic.
Product Name : BMS-986353
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 13, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
HRS-9813 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Pulmonary Fibrosis.
Lead Product(s): HRS-9813,Nintedanib Esylate,Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HRS-9813,Nintedanib Esylate,Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
Details : HRS-9813 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nintedanib Esylate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Lead Product(s): Nintedanib Esylate,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nintedanib Esylate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nintedanib Esylate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nalbuphine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Nalbuphine Hydrochloride,Pirfenidone,Nintedanib Esylate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nalbuphine Hydrochloride,Pirfenidone,Nintedanib Esylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pirfenidone + Nintedanib + NAL ER PK Interaction In Healthy Participants
Details : Nalbuphine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AP02 (nintedanib esylate ) is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Being investigated for idiopathic pulmonary fibrosis.
Lead Product(s): Nintedanib Esylate,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nintedanib Esylate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Avalyn Completes Phase 1 AP02 Trial, Eyes Phase 2 in Lung Fibrosis
Details : AP02 (nintedanib esylate ) is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Being investigated for idiopathic pulmonary fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2025

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]methyl 1-acetyl-3-(methoxy(phenyl)methylene)-2-oxo...
CAS Number : 1168152-07-5
End Use API : Nintedanib Esylate
About The Company : Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. I...
N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-...
CAS Number : 262368-30-9
End Use API : Nintedanib Esylate
About The Company : Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. I...
Methyl-1-(Chloro Acetyl)-2- Oxoindoline-6-Carboxyl...
CAS Number : CAS-1160293-25-3
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

CAS Number : CAS-14192-26-8
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

1,3-Dimethyl 2-[4- (Methoxycarbonyl)-2- Nitropheny...
CAS Number : CAS-1160293-27-5
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

(Z)-Methyl 1-(2-Chloroacetyl)- 3- (Methoxy (Phenyl...
CAS Number : CAS-1160293-24-2
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

Methyl 3-[Methoxy (Phenyl)Methylene]-2- Oxoindolin...
CAS Number : CAS-1160293-22-0
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

METHYL-1-ACETYL-2-OXOINDOLINE-6-CARBOXYLATE
CAS Number : 676326-36-6
End Use API : Nintedanib Esylate
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

METHYL-4-CHLORO-3-NITRO BENZOIC ACID
CAS Number : 14719-83-6
End Use API : Nintedanib Esylate
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

CAS Number : 100-15-2
End Use API : Nintedanib Esylate
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
16
PharmaCompass offers a list of Nintedanib Esylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nintedanib Esylate manufacturer or Nintedanib Esylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nintedanib Esylate manufacturer or Nintedanib Esylate supplier.
A Nintedanib Esylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nintedanib Esylate, including repackagers and relabelers. The FDA regulates Nintedanib Esylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nintedanib Esylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nintedanib Esylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Nintedanib Esylate supplier is an individual or a company that provides Nintedanib Esylate active pharmaceutical ingredient (API) or Nintedanib Esylate finished formulations upon request. The Nintedanib Esylate suppliers may include Nintedanib Esylate API manufacturers, exporters, distributors and traders.
click here to find a list of Nintedanib Esylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Nintedanib Esylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Nintedanib Esylate active pharmaceutical ingredient (API) in detail. Different forms of Nintedanib Esylate DMFs exist exist since differing nations have different regulations, such as Nintedanib Esylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nintedanib Esylate DMF submitted to regulatory agencies in the US is known as a USDMF. Nintedanib Esylate USDMF includes data on Nintedanib Esylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nintedanib Esylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nintedanib Esylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nintedanib Esylate Drug Master File in Korea (Nintedanib Esylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nintedanib Esylate. The MFDS reviews the Nintedanib Esylate KDMF as part of the drug registration process and uses the information provided in the Nintedanib Esylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nintedanib Esylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nintedanib Esylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nintedanib Esylate suppliers with KDMF on PharmaCompass.
A Nintedanib Esylate written confirmation (Nintedanib Esylate WC) is an official document issued by a regulatory agency to a Nintedanib Esylate manufacturer, verifying that the manufacturing facility of a Nintedanib Esylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nintedanib Esylate APIs or Nintedanib Esylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Nintedanib Esylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Nintedanib Esylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nintedanib Esylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nintedanib Esylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nintedanib Esylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nintedanib Esylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nintedanib Esylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nintedanib Esylate suppliers with NDC on PharmaCompass.
Nintedanib Esylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nintedanib Esylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nintedanib Esylate GMP manufacturer or Nintedanib Esylate GMP API supplier for your needs.
A Nintedanib Esylate CoA (Certificate of Analysis) is a formal document that attests to Nintedanib Esylate's compliance with Nintedanib Esylate specifications and serves as a tool for batch-level quality control.
Nintedanib Esylate CoA mostly includes findings from lab analyses of a specific batch. For each Nintedanib Esylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nintedanib Esylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Nintedanib Esylate EP), Nintedanib Esylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nintedanib Esylate USP).